Hailegebriel Tamirat, Nibret Endalkachew, Munshea Abaineh
Department of Biology, College of Science, Bahir Dar University, Bahir Dar, Ethiopia.
Biotechnology Research Institute (BRI), Bahir Dar University, Bahir Dar, Ethiopia.
J Trop Med. 2021 Dec 20;2021:2625255. doi: 10.1155/2021/2625255. eCollection 2021.
Schistosomiasis is one of the neglected tropical diseases causing a serious human health problem in Ethiopia. Praziquantel is the only drug that has been used for the treatment of human schistosomiasis in the country. In line with this, the efficacy of praziquantel has been evaluated in a few interventional studies in the country, but there is a lack in systematically gathered and analyzed information for policymakers. The aim of this systematic review and meta-analysis was to provide a summary of the efficacy of praziquantel for the treatment of human schistosomiasis in Ethiopia.
We conducted a literature search from ScienceDirect, PubMed/Medlin, and Google Scholar databases. A total of 140 articles published in English from 1980 to June 2021 were accessed and 15 of them were eligible for this meta-analysis. The meta-analysis was conducted using Stata 14 software, "metan command." The heterogeneities among studies were evaluated using test.
A total of 140 articles were reviewed, but only 15 of them fulfilled the inclusion criteria. The polled cure rate of 40 mg/kg praziquantel was 89.2% (95% CI: 85.4-93.1) and 93.6% (95% CI: 80.6-106) among and , respectively. Similarly, the mean egg reduction rates of 40 mg/kg praziquantel were 90.2% and 85% among and infected subjects, respectively. The common adverse events observed after receiving praziquantel include abdominal pain, vomiting, headache, diarrhea, and bloody stool.
This systematic review and meta-analysis has indicated that praziquantel is still an appropriate drug for the treatment of human schistosomiasis in Ethiopia.
血吸虫病是一种被忽视的热带疾病，在埃塞俄比亚造成严重的人类健康问题。吡喹酮是该国唯一用于治疗人类血吸虫病的药物。与此一致的是，该国已在一些干预性研究中评估了吡喹酮的疗效，但缺乏为政策制定者系统收集和分析的信息。本系统评价和荟萃分析的目的是总结吡喹酮治疗埃塞俄比亚人类血吸虫病的疗效。
我们在科学Direct、PubMed/Medline和谷歌学术数据库中进行了文献检索。共检索到1980年至2021年6月以英文发表的140篇文章，其中15篇符合本荟萃分析的条件。使用Stata 14软件的“metan命令”进行荟萃分析。使用 检验评估研究之间的异质性。
共审查了140篇文章，但只有15篇符合纳入标准。40mg/kg吡喹酮的汇总治愈率在 和 中分别为89.2%（95%CI：85.4-93.1）和93.6%（95%CI：80.6-106）。同样，40mg/kg吡喹酮在 和 感染受试者中的平均虫卵减少率分别为90.2%和85%。服用吡喹酮后观察到的常见不良事件包括腹痛、呕吐、头痛、腹泻和血便。
本系统评价和荟萃分析表明，吡喹酮仍然是埃塞俄比亚治疗人类血吸虫病的合适药物。
